Medical Research Breakthroughs

Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa

MALVERN, Pa., March 02, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that enrollment is now complete for the OCU400 Phase 3 liMeliGhT clinical trial for retinitis pigmentosa (RP). As a one-year clinical trial, topline...

Lupita Nyong’o Once Thought Her Uterine Fibroid Symptoms Were Normal. Here Are 6 Sneaky Signs

It’s not always just a “bad period.”

A bold new plan could finally cure type 1 diabetes

Researchers are developing a two-part therapy for type 1 diabetes: lab-made insulin-producing cells paired with custom-engineered immune cells that protect them. The goal is to stop the immune system from destroying transplanted cells — without using immunosuppressive drugs. Backed by $1 million in funding, the team hopes to create a...

Hope for colorectal cancer patients as Nigeria begins immunotherapy trial

Nigeria launches its first immunotherapy clinical trial for colorectal cancer, offering new hope and free treatment for patients with an advanced stage ofRead More: https://punchng.com/hope-for-colorectal-cancer-patients-as-nigeria-begins-immunotherapy-trial/

Psychedelicnewsbreaks Nrx Pharmaceuticals, Inc. (NASDAQ: NRXP) Appoints Prof. Joshua C. Brown As Chief Medical Innovation Officer

(MENAFN - Investor Brand Network)NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, has appointed Prof. Joshua C. Brown, MD, PhD, as Chief Medical Innovation Officer. ...

Artificial Intelligence in Medical Diagnostics Market to Reach USD 8.08 Billion by 2032, Growing at 22.31% CAGR Amid Rising Demand for Precision Healthcare, analyses DelveInsight

The global Artificial Intelligence (AI) in Medical Diagnostics Market is entering a transformative growth phase, with its valuation projected to surge from USD 1,623.20 million in 2024 to USD 8,081.97 million by 2032. Expanding at a robust CAGR of 22.31%

Metabolic Dysfunction-Associated Steatohepatitis Drugs Market to Reach US$ 929.05 Million by 2033 at 18.1% CAGR; North America Leads with 42% Share - Key Players: Madrigal, Novo Nordisk, Boehringer Ingelheim

The global metabolic dysfunction-associated steatohepatitis (MASH) market size reached US$ 180.1 million in 2024 is expected to reach US$ 929.05 million by 2033, growing at a CAGR of 18.1% during the forecast period 2025-2033. The global Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Talphera Announces 50% Enrollment Milestone in Ongoing NEPHRO-CRRT Registrational Trial

Enrolled 35 of the 70 patients in the ongoing NEPHRO-CRRT registrational study, supported by new target profile sites Company to host a virtual investor and analyst event on March 23 at 11:00 am ET featuring nephrologists, Dr. Blaithin McMahon and Dr. Joao Teixeira SAN MATEO, Calif.,...

Hua Medicine Announces the Approval of Dorzagliatin for Marketing in Hong Kong SAR, China | AAP

Hua Medicine Announces the Approval of Dorzagliatin for Marketing in Hong Kong SAR, China

First glucokinase-activator (GKA) approval outside mainland China Approval supports a differentiated approach to Type 2 diabetes (T2D) management Hong Kong will serve as Hua Medicine’s launchpad for international market expansion SHANGHAI and HONG KONG, March 3, 2026 /PRNewswire/ — Hua Medicine (“the Company”, Hong Kong Stock Exchange Stock...